Enasidenib’s mechanism of action

Enasidenib (Enasidenib) is a drug used to treat certain types of acute myeloid leukemia (AML). It belongs to the class of IDH2 (isocitrate dehydrogenase 2) inhibitors. The mechanism of action of ensidipine is to inhibit the abnormalIDH2 enzyme activity and reduce the accumulation of 2-HG, thereby inhibiting the proliferation and survival of AML cells.

Under normal circumstances,IDH2 participates in the citric acid cycle within cells and helps maintain the normal metabolic process of cells. However, in some patients with acute myeloid leukemia, the IDH2 gene is mutated, resulting in abnormally enhanced enzyme activity, which in turn triggers abnormal metabolic pathways. These mutations cause excessive accumulation of a metabolite produced by IDH2 called 2-hydroxyglutarate (2-HG). Excessive accumulation of 2-HG interferes with normal cell functions and promotes the proliferation and survival of leukemia cells. By inhibiting the activity of abnormal IDH2, ensidipine reduces the production and accumulation of 2-HG and blocks the abnormal IDH2 metabolic pathway, thereby inhibiting the proliferation and survival of leukemia cells.

Encidipine research medicine is not currently on the market in China, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.